A Study of CCX140-B in Subjects With FSGS

Amgen

Status and phase: Completed; Phase 2

Conditions: FSGS; Glomerulosclerosis; Focal Segmental Glomerulosclerosis

Treatments: Other: Placebo; Drug: CCX140-B

Study type: Interventional

Funder types: Industry

Identifiers

NCT03536754

NCT03536754 (Other Identifier)

134007 (Other Identifier)

CL011_140

LUMINA-1 (Other Identifier)

Details and patient eligibility

About

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia

Full description

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) to be conducted in the North America, Europe and Australia. The aim of this study is to evaluate the effect of treatment with CCX140-B, a selective antagonist of C-C chemokine receptor type 2 in subjects with focal segmental glomerulosclerosis on urinary protein excretion as assessed by changes in urine protein to creatinine ratio (UPCR).

Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Enrollment: 46 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female subjects aged 18-75
2. UPCR ≥ 1 g protein/g creatinine (or at 113 mg.mmol) at screening
3. Diagnosis of FSGS based on renal biopsy or high risk genetic variant
4. Diagnosis of one of primary FSGS based on characteristic histopathology, medical history and clinical course or FSGS secondary to genetic variants associated with increased risk or severity.
5. Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73m2
6. Clinical stable blood pressure not to exceed 145/95 mmHg
7. RAAS blockers must be stable for at least 4 weeks prior to screening and projected to remain stable through week 12, unless adjustments are required for management of hypertension.
8. Immunosuppressive or immunomodulatory therapy must be stable for at least 4 weeks prior to screening and projected to remain stable through study week 12
9. Glucocorticoids must be stable for at least 4 weeks prior to screening and projected to remain stable through study week 12.
10. Both genders of childbearing potential must agree to use adequate contraception during and for at least 3 months after the last dose of study drug.
11. Subjects must be willing and able to give written Informed Consent and to comply with protocol requirements.
12. Subjects must be judged to be otherwise fit for the study by the Investigator. -

Exclusion criteria

1. Pregnant or nursing

2. History of organ transplantation

3. On an organ transplant waiting list or anticipated organ transplant within 6 months of screening

4. Anti-CD20 monoclonal antibodies within 20 months of screening are exclusionary. Subjects that used anti CD20 monoclonal antibodies prior to week 20 are allowed with confirmed recovery of CD20+ B cell population to within normal range

5. Plasmapheresis within 12 weeks of screening

6. BMI ≥40

7. Participation in any clinical study of an investigational product within 12 weeks or 5 half-lives of screening

8. Currently on dialysis or likely to require dialysis during the blinded treatment phase of the study.

9. History or presence of any form of cancer within 5 years of screening except excised basal cell or squamous cell carcinoma or carcinoma in situ such as cervical or breast carcinoma in situ that has been excised or completed resected without evidence or recurrence.

10. Positive HBV, HCV, or HIV viral screening test. Subjects who have received highly effective therapy for HCV demonstrated to have negative viral titers for at least 6 months following discontinuation of treatment, will be considered to have a negative HCV screening test

11. Renal disease associated with disorders other than FSGS that is active or has significant risk of progressing during the course of the study.

12. Disorders that are associated with FSGS lesions.

13. Evidence of tuberculosis.

14. Evidence of hepatic disease with the exception that isolated INR elevation in the absence of other significant liver enzyme abnormalities is explained by anticoagulant therapy, (e.g. warfarin)

15. Hematologic abnormalities as follows: Hb <8 g/dL, platelets <50,000, ANC <1000 cells/µL) at baseline.

16. QTcF greater than 450 msec.

17. History of alcohol or illicit drug abuse or of lithium, pamidronate and interferon. Recreational use of cannabis is not excluded where legal.

18. History of gastrointestinal conditions that may interfere with study medication compliance.

19. Known hypersensitivity to CCX140-B or inactive ingredients of the CCX140-B tablets (including microcrystalline cellulose, starch, crospovidone, magnesium stearate, or silicon dioxide).

20. History or presence of systemic disorder other than FSGS that requires, or is expected to require, systemic glucocorticoids or immune modulators during the study; topical or inhaled glucocorticoids and immune modulators are not excluded.

21. History or presence of any medical condition or disease which, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation.

22. Subjects taking strong CYP3A4 inducers or strong CYP3A4 inhibitors within two weeks prior to screening.

23. Subjects taking lithium or interferon; subjects taking non-steroidal anti-inflammatory agents (NSAIDS) chronically (intermittent, i.e. occasional NSAIDS for pain or fever is discouraged, but is not excluded).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

46 participants in 4 patient groups, including a placebo group

Group A

Placebo Comparator group

Description:

Placebo (N=10)

Treatment:

Other: Placebo

Group B

Experimental group

Description:

CCX140-B 5 mg once daily (N=10)

Treatment:

Drug: CCX140-B

Drug: CCX140-B

Drug: CCX140-B

Group C

Experimental group

Description:

CCX140-B 10 mg twice daily (N=10)

Treatment:

Drug: CCX140-B

Drug: CCX140-B

Drug: CCX140-B

Group D

Experimental group

Description:

CCX140-B 15 mg twice daily (N=10)

Treatment:

Drug: CCX140-B

Drug: CCX140-B

Drug: CCX140-B